Oncopeptides AB (ONCO) - Net Assets

Latest as of December 2025: Skr-58.89 Million SEK ≈ $-6.34 Million USD

Based on the latest financial reports, Oncopeptides AB (ONCO) has net assets worth Skr-58.89 Million SEK (≈ $-6.34 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr134.84 Million ≈ $14.51 Million USD) and total liabilities (Skr193.73 Million ≈ $20.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ONCO tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr-58.89 Million
% of Total Assets	-43.67%
Annual Growth Rate	N/A
5-Year Change	-127.93%
10-Year Change	-323.61%
Growth Volatility	466.99

Oncopeptides AB - Net Assets Trend (2014–2025)

This chart illustrates how Oncopeptides AB's net assets have evolved over time, based on quarterly financial data. See ONCO cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Oncopeptides AB (2014–2025)

The table below shows the annual net assets of Oncopeptides AB from 2014 to 2025. For live valuation and market cap data, see Oncopeptides AB (ONCO) total market value.

Year	Net Assets	Change
2025-12-31	Skr-58.89 Million ≈ $-6.34 Million	-208.48%
2024-12-31	Skr54.28 Million ≈ $5.84 Million	-4.39%
2023-12-31	Skr56.78 Million ≈ $6.11 Million	-80.71%
2022-12-31	Skr294.29 Million ≈ $31.67 Million	+39.56%
2021-12-31	Skr210.87 Million ≈ $22.69 Million	-63.45%
2020-12-31	Skr576.90 Million ≈ $62.08 Million	-27.62%
2019-12-31	Skr797.01 Million ≈ $85.77 Million	+152.35%
2018-12-31	Skr315.83 Million ≈ $33.99 Million	-24.44%
2017-12-31	Skr418.00 Million ≈ $44.98 Million	+1487.15%
2016-12-31	Skr26.34 Million ≈ $2.83 Million	+1112.95%
2015-12-31	Skr-2.60 Million ≈ $-279.80K	-134.19%
2014-12-31	Skr7.61 Million ≈ $818.48K	--

Equity Component Analysis

This analysis shows how different components contribute to Oncopeptides AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 577311530500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr30.30 Million	%
Other Components	Skr5.81 Billion	%
Total Equity	Skr-58.89 Million	100.00%

Oncopeptides AB Competitors by Market Cap

The table below lists competitors of Oncopeptides AB ranked by their market capitalization.

Company	Market Cap
BQE Water Inc V:BQE	$66.70 Million
RENERGEN LTD CDI/1:1 F:996	$66.72 Million
Doosan Fuel Cell Co. Ltd. Pfd. Series 1 KO:33626K	$66.74 Million
AIFORIA TECHNOLOGIES OYJ F:L6J	$66.76 Million
Nusa Raya Cipta Tbk JK:NRCA	$66.69 Million
Abra Information Technologies Ltd TA:BBYL	$66.65 Million
Aureus Greenway Holdings Inc. Common Stock NASDAQ:AGH	$66.64 Million
Argosy Minerals Ltd AU:AGY	$66.62 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Oncopeptides AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 54,285,000 to -58,891,000, a change of -113,176,000 (-208.5%).
Net loss of 249,585,000 reduced equity.
New share issuances of 151,407,000 increased equity.
Other comprehensive income increased equity by 2,843,000.
Other factors decreased equity by 17,841,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-249.59 Million	-423.81%
Share Issuances	Skr151.41 Million	+257.1%
Other Comprehensive Income	Skr2.84 Million	+4.83%
Other Changes	Skr-17.84 Million	-30.29%
Total Change	Skr-	-208.48%

Book Value vs Market Value Analysis

This analysis compares Oncopeptides AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2014-12-31	Skr0.20	Skr1.63	x
2015-12-31	Skr-0.07	Skr1.63	x
2016-12-31	Skr0.68	Skr1.63	x
2017-12-31	Skr10.78	Skr1.63	x
2018-12-31	Skr7.36	Skr1.63	x
2019-12-31	Skr15.42	Skr1.63	x
2020-12-31	Skr9.25	Skr1.63	x
2021-12-31	Skr2.80	Skr1.63	x
2022-12-31	Skr3.57	Skr1.63	x
2023-12-31	Skr0.45	Skr1.63	x
2024-12-31	Skr0.33	Skr1.63	x
2025-12-31	Skr-0.26	Skr1.63	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Oncopeptides AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -350.94%
• Asset Turnover: 0.53x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-265.60%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-435.13%	0.00%	0.00x	1.73x	Skr-33.85 Million
2015	0.00%	0.00%	0.00x	0.00x	Skr-53.08 Million
2016	-434.55%	0.00%	0.00x	2.11x	Skr-117.08 Million
2017	-59.24%	0.00%	0.00x	1.15x	Skr-289.42 Million
2018	-132.81%	0.00%	0.00x	1.41x	Skr-451.03 Million
2019	-92.94%	0.00%	0.00x	1.25x	Skr-820.41 Million
2020	-276.43%	-8239.18%	0.02x	1.64x	Skr-1.65 Billion
2021	-678.30%	-1209.11%	0.27x	2.08x	Skr-1.45 Billion
2022	-114.83%	-4044.90%	0.02x	1.31x	Skr-367.38 Million
2023	-438.73%	-707.30%	0.15x	4.20x	Skr-254.79 Million
2024	-524.28%	-899.29%	0.13x	4.50x	Skr-290.04 Million
2025	0.00%	-350.94%	0.53x	0.00x	Skr-243.70 Million

Industry Comparison

This section compares Oncopeptides AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $159,185,570
Average return on equity (ROE) among peers: -26.34%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Oncopeptides AB (ONCO)	Skr-58.89 Million	-435.13%	N/A	$66.69 Million
2cureX AB (2CUREX)	$74.34 Million	-25.47%	0.06x	$5.16 Million
Ascelia Pharma AB (publ) (ACE)	$237.06 Million	-16.83%	0.06x	$41.03 Million
AcouSort AB (ACOU)	$376.48K	28.69%	1.44x	$9.52 Million
Active Biotech AB (ACTI)	$46.67 Million	-106.88%	0.22x	$103.60 Million
Alzinova AB (ALZ)	$105.53 Million	-12.38%	0.06x	$8.00 Million
AlzeCure Pharma (ALZCUR)	$233.17 Million	-15.43%	0.02x	$46.62 Million
Annexin Pharmaceuticals AB (ANNX)	$15.57 Million	-63.12%	0.51x	$9.23 Million
Alligator Bioscience AB (ATORX)	$41.44 Million	0.00%	0.15x	$11.36 Million
BioInvent International AB (BINV)	$49.01 Million	-36.81%	0.66x	$163.58 Million
BioArctic AB (publ) (BIOA-B)	$788.68 Million	-15.19%	0.14x	$2.39 Billion

About Oncopeptides AB

ST:ONCO Sweden Biotechnology

Market Cap

$66.69 Million

Skr619.75 Million SEK

Market Cap Rank

#20863 Global

#376 in Sweden

Share Price

Skr1.63

Change (1 day)

-0.55%

52-Week Range

Skr1.27 - Skr6.31

All Time High

Skr343.59